Page 34 - Read Online
P. 34

Smetanina et al. Vessel Plus 2021;5:19  https://dx.doi.org/10.20517/2574-1209.2021.17  Page 13 of 13

               52.      Kakkos SK, Nicolaides AN. Efficacy of micronized purified flavonoid fraction (Daflon®) on improving individual symptoms, signs
                   and quality of life in patients with chronic venous disease: a systematic review and meta-analysis of randomized double-blind placebo-
                   controlled trials. Int Angiol 2018;37:143-54.  DOI  PubMed
               53.      Rodnyansky DV, Fokin AA. [Diosmin-containing phlebotropic drugs in varicose eczema]. Angiol Sosud Khir 2019;25:88-92.  DOI
                   PubMed
               54.      Kurginyan HM, Raskin VV. Modern view on the therapy of chronic venous insufficiency with micronized purified flavonoid fraction.
                   Cardiovasc Ther Prev 2020;19:2592.
               55.      Ponomarev ÉA, Strepetov NN, Sotnikov IE, et al. [Use of Detravenol in treatment of chronic venous insufficiency of lower limbs].
                   Angiol Sosud Khir 2020;26:95-102.  DOI  PubMed
               56.      Raffetto JD, Eberhardt RT, Dean SM, Ligi D, Mannello F. Pharmacologic treatment to improve venous leg ulcer healing. J Vasc Surg
                   Venous Lymphat Disord 2016;4:371-4.  DOI  PubMed
               57.      Bush R, Comerota A, Meissner M, Raffetto JD, Hahn SR, Freeman K. Recommendations for the medical management of chronic
                   venous disease: The role of Micronized Purified Flavanoid Fraction (MPFF). Phlebology 2017;32:3-19.  DOI  PubMed
               58.      Melin MM, Dean SM. RE: A literature review of pharmacological agents to improve venous leg ulcer healing. Letter to the Editor.
                   Wounds 2020;32:A10.
               59.      U.S. Department of Health & Human Services, National Institutes of Health, NCATS. Inxight: Drugs. Vasculera. Available from:
                   https://drugs.ncats.io/drug/Z7R65IFU98. [Last accessed on 12 Mar 2021].
               60.      Casili G, Lanza M, Campolo M, et al. Therapeutic potential of flavonoids in the treatment of chronic venous insufficiency. Vascul
                   Pharmacol 2021;137:106825.  DOI  PubMed
               61.      U.S. Department of Health & Human Services, National Institutes of Health, NCATS. Inxight: Drugs. Diosmin. Available from:
                   https://drugs.ncats.io/drug/7QM776WJ5N. [Last accessed on 12 Mar 2021].
               62.      Sirtori CR. Aescin: pharmacology, pharmacokinetics and therapeutic profile. Pharmacol Res 2001;44:183-93.  DOI  PubMed
               63.      Stücker M, Debus ES, Hoffmann J, et al. Consensus statement on the symptom-based treatment of chronic venous diseases. J Dtsch
                   Dermatol Ges 2016;14:575-83.  DOI  PubMed
               64.      Peralta GR, Arévalo Gardoqui J, Llamas Macías FJ, Navarro Ceja VH, Mendoza Cisneros SA, Martínez Macías CG. Clinical and
                   capillaroscopic evaluation in the treatment of chronic venous insufficiency with Ruscus aculeatus, hesperidin methylchalcone and
                   ascorbic acid in venous insufficiency treatment of ambulatory patients. Int Angiol 2007;26:378-84.  PubMed
               65.      Almeida Cyrino FZG, Balthazar DS, Sicuro FL, Bouskela E. Effects of venotonic drugs on the microcirculation: Comparison between
                   Ruscus extract and micronized diosmine1. Clin Hemorheol Microcirc 2018;68:371-82.  DOI  PubMed
               66.      Kiesewetter H, Koscielny J, Kalus U, et al. Efficacy of orally administered extract of red vine leaf AS 195 (folia vitis viniferae) in
                   chronic venous insufficiency (stages I-II). A randomized, double-blind, placebo-controlled trial. Arzneimittelforschung 2000;50:109-
                   17.  DOI  PubMed
               67.      Rabe E, Stücker M, Esperester A, Schäfer E, Ottillinger B. Efficacy and tolerability of a red-vine-leaf extract in patients suffering from
                   chronic venous insufficiency--results of a double-blind placebo-controlled study. Eur J Vasc Endovasc Surg 2011;41:540-7.  DOI
                   PubMed
               68.      Elleuch N, Zidi H, Bellamine Z, Hamdane A, Guerchi M, Jellazi N; CVD study investigators. Sulodexide in Patients with Chronic
                   Venous Disease of the Lower Limbs: Clinical Efficacy and Impact on Quality of Life. Adv Ther 2016;33:1536-49.  DOI  PubMed
                   PMC
               69.      Chupin AV, Katorkin SE, Katel’nitskiĭ II, et al. Sulodexide in treatment of chronic venous insufficiency. Results of the All-Russian
                   multicenter programme ACVEDUCT. Angiol Sosud Khir 2018;24:47-55. (in Russian).  PubMed
               70.      Carroll BJ, Piazza G, Goldhaber SZ. Sulodexide in venous disease. J Thromb Haemost 2019;17:31-8.  DOI  PubMed
               71.      Gohil KJ, Patel JA, Gajjar AK. Pharmacological Review on Centella asiatica: A Potential Herbal Cure-all. Indian J Pharm Sci
                   2010;72:546-56.  DOI  PubMed  PMC
               72.      Martinez-Zapata MJ, Vernooij RW, Simancas-Racines D, et al. Phlebotonics for venous insufficiency. Cochrane Database Syst Rev
                   2020;11:CD003229.  DOI  PubMed
               73.      Karetová D, Suchopár J, Bultas J. Diosmin/hesperidin: a cooperating tandem, or is diosmin crucial and hesperidin an inactive
                   ingredient only? Vnitr Lek 2020;66:97-103.  PubMed
               74.      Lust L, Kuk H, Kohlhaas J, Sticht C, Korff T. Inhibition of cyclooxygenase activity by diclofenac attenuates varicose remodeling of
                   mouse veins. Vessel Plus 2021;5:7.  DOI
   29   30   31   32   33   34   35   36   37   38   39